ClinicalTrials.gg
Active, not recruitingNCT05333068Updated Jun 3, 2026

COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

An interventional study of PCI revascularization strategy based on combined FFR and OCT assessment and PCI revascularization strategy based FFR assessment in Multivessel Coronary Artery Disease, Ischemia and Vulnerable Plaque, sponsored by Diagram B.V.. Active, not recruiting at 49 sites in 18 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Diagram B.V. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,223
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Ischemia with a site in Spain — 5 open to participants now, 8 under way, 1 of them phase 3. Ischemia · Spain.

Enrollment
3rd of 16
1,223 · median 181
Started
2022
with 3 others
No phase
7 of 27
2 open now
Registered
19th of 27
by date
Lead sponsor
1 of 27
Diagram B.V.

Among the 27 studies in Ischemia with a site in Spain, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2022, is one of 7 with no phase, and was the 19th registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 71 are open to participants now.

Browse Ischemia studies →

Open to participants now

5 of the 27 studies in Ischemia with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Ischemia with a site in Spain, or all of them as a file.
02

Study summary

The COMBINE-INTERVENE Trial will investigate whether a PCI revascularization strategy based on combined FFR and OCT assessment is superior to a PCI revascularization strategy based on FFR-alone in patients with MVD with any presentation.

Read the detailed description

The published COMBINE trial shows that patients carrying an OCT-detected thin-cap atheroma have a fivefold higher rate of the primary endpoint compared to patients without vulnerable lesion morphology, despite absence of ischemia. The most important finding of this trial is that not ischemia, but underlying lesion morphology could be the most important factor that predicts future adverse events. Together with the recently published ISCHEMIA trial, where ischemia guided revascularization failed to improve clinical outcomes compared to medical treatment, the COMBINE trial leads to a new way of thinking in interventional cardiology and also opens the door for new treatment strategies where a combined ischemic and morphologic assessment could lead to better clinical outcomes.

The COMBINE-INTERVENE Trial will investigate whether a PCI revascularization strategy based on combined FFR and OCT assessment is superior to a PCI revascularization strategy based on FFR-alone in patients with MVD with any presentation. The COMBINE-INTERVENE Trial is the first in line trial that will test focal percutaneous stenting for vulnerable plaque lesions independently from ischemia.

03

Conditions studied

  • Multivessel Coronary Artery Disease
  • Ischemia
  • Vulnerable Plaque
  • Coronary Artery Disease
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients undergoing PCI, aged 30-80 years with any clinical presentation
  2. Angiographic criteria: presence of ≥ 2 de novo target lesions* located in 2 different native coronary arteries feasible for treatment with PCI (operator / Heart team decision)

Angiographic criteria target lesion* (all criteria I-IV should be applicable):

I. DS ≥ 50% on visual estimation II. de novo lesion located in native (non-grafted) vessel III. lesion reference diameter of ≥ 2.0 mm IV. Thrombolysis In Myocardial Infarction (TIMI) 3 flow in all vessels (with exclusion of culprit lesions if MI at presentation)

*Target lesions are either culprit MI lesions or lesions where FFR will be performed. Patients are eligible if they have ≥ 2 target lesions or one culprit and ≥ 1 target lesion.

Exclusion criteria

Exclusion Criteria:

  1. Patients with MVD requiring coronary artery bypass grafting (CABG) treatment (operator / local heart team decision)
  2. Lesion located in a grafted segment or in a vein graft
  3. In-stent restenosis lesions
  4. Left main trifurcation
  5. Left main lesion stand-alone (without other lesions)
  6. Patients with severe tortuous lesions (where FFR and OCT is judged impossible or dangerous)
  7. Chronic total occlusion
  8. Spontaneous coronary dissection
  9. Patients with severe valvular heart disease likely to require cardiac surgery within the next 2 years
  10. Patients with left ventricle (LV) function less than 30%
  11. Renal insufficiency ( (GFR) \< 29 ml/min/1.73m2; Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5)
  12. less than 3 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,223 participants (actual)

Study arms

  • Experimental
    MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment

    MVD \> 2 50% angiographic stenosis PCI revascularization strategy based FFR and OCT assessment

    Procedure: PCI revascularization strategy based on combined FFR and OCT assessment

  • Sham comparator
    MVD > 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)

    MVD \> 2 50% angiographic stenosis PCI revascularization strategy based FFR assessment (and sham OCT)

    Procedure: PCI revascularization strategy based FFR assessment

Interventions

  • ProcedurePCI revascularization strategy based on combined FFR and OCT assessment

    PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with \> 70 % AS or MLA \< 2.5 mm2.

  • ProcedurePCI revascularization strategy based FFR assessment

    PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)

06

What researchers measure

Primary outcomes

  1. Cardiac death, any MI or any clinically driven revascularization at 24 months between FFR&OCT guided revascularization versus FFR-guided revascularization

    Cardiac death, any MI or any clinically driven revascularization at 24 months between FFR\&OCT guided revascularization versus FFR-guided revascularization

    Time frame: 24 months

Secondary outcomes

  1. Cardiac death, any MI or any clinical-driven revascularization at 24 months excluding TLR events occurring from medically treated lesions with a FFR between 0.76-0.80 in the experimental arm

    Cardiac death, any MI or any clinical-driven revascularization at 24 months excluding TLR events occurring from medically treated lesions with a FFR between 0.76-0.80 in the experimental arm

    Time frame: 24 months

  2. Cardiac death, any spontaneous MI or any clinically-driven revascularization at 24 months

    Cardiac death, any spontaneous MI or any clinically-driven revascularization at 24 months

    Time frame: 24 months

  3. Cardiac death, any spontaneous MI or any clinically driven revascularization at 24 months

    Cardiac death, any spontaneous MI or any clinically driven revascularization at 24 months

    Time frame: 24 months

  4. Analysis of corelab-approved primary endpoints, as per protocol analysis

    Analysis of corelab-approved primary endpoints, as per protocol analysis

    Time frame: 24 months

07

Study locations

49 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Sep 2026, 54 months after the start.

Of 72 non-industry interventional studies with no phase under Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 54 months is above that.

Counting every sponsor, half of 83 studies reached it within 31 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2022
First posted
Apr 18, 2022
StartActual
Mar 16, 2022
Primary completionEst.
Sep 16, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05333068
Lead sponsor
Diagram B.V.
Collaborators
Abbott
Responsible party
Sponsor
First posted
Apr 18, 2022
Start date
Mar 16, 2022
Primary completion
Sep 16, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

Elvin Kedhi, Prof.dr.
principal investigator · Professor of Medicine McGill University; Director Intervention Cardiology, McGill University Health Center, Canada; Visiting Professor, Silesian Medical University Katowice, Poland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion